Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.98 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.98 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.98 |
| ▸ | ABCC3 | O15438 | 2/20 | 0.98 |
| ▸ | ABCC4 | O15439 | 2/20 | 0.98 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.98 |
| ▸ | HTR2A | P28223 | 2/20 | 0.98 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.98 |
| ▸ | HPGD | P15428 | 2/20 | 0.98 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.98 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.98 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.98 |
| ▸ | RARA | P10276 | 1/20 | 0.98 |
| ▸ | RARB | P10826 | 1/20 | 0.98 |
| ▸ | RARG | P13631 | 1/20 | 0.98 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.98 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.98 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.98 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.98 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gliquidone SCHEMBL29465034 | 0.99 | LMNA (1.00) | LMNACYP3A4CYP2C9ABCC3ABCC4 | |
| Gliquidone SCHEMBL15669239 | 0.99 | LMNA (1.00) | LMNACYP3A4CYP2C9ABCC3ABCC4 | |
| Gliquidone SCHEMBL37769 | 0.99 | LMNA (1.00) | LMNACYP3A4CYP2C9ABCC3ABCC4 | |
| SCHEMBL8216020 | 0.92 | LMNA (0.87) | LMNACYP3A4CYP2C9ABCC3ABCC4 | |
| Gliquidone SCHEMBL28086518 | 0.90 | LMNA (0.82) | LMNACYP3A4CYP2C9ABCC3ABCC4 | |
| Gliquidone SCHEMBL21824303 | 0.88 | CYP2C9 (0.79) | LMNACYP3A4CYP2C9ABCC3ABCC4 | |
| Gliquidone SCHEMBL27714721 | 0.88 | CYP2C9 (0.78) | LMNACYP3A4CYP2C9ABCC3ABCC4 | |
| SCHEMBL10281162 | 0.85 | CYP3A4 (0.76) | LMNACYP3A4CYP2C9ABCC3ABCC4 | |
| SCHEMBL11929012 | 0.85 | CYP3A4 (0.76) | LMNACYP3A4CYP2C9ABCC3ABCC4 | |
| SCHEMBL25866045 | 0.85 | CYP3A4 (0.75) | LMNACYP3A4CYP2C9ABCC3ABCC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8541456-B2 | Roflumilast for the treatment of diabetes mellitus type 2 | TAKEDA GMBH (DE) | 2013-09-24 | — | — | US | disclosed |
| US-20120129817-A1 | COMBINATION TREATMENT FOR DIABETES MELLITUS | NYCOMED GMBH (DE) | 2012-05-24 | — | — | US | disclosed |
| US-20110269750-A1 | ROFLUMILAST FOR THE TREATMENT OF DIABETES MELLITUS | NYCOMED GMBH (DE) | 2011-11-03 | — | — | US | disclosed |
| US-8017633-B2 | Administering [3-cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-dichloropyrid-4-yl)benzamide; hypertension, hyperlipidemia, hyperuricemia, gout and hypercoagulability | NYCOMED GMBH (DE) | 2011-09-13 | — | — | US | disclosed |
| EP-2213289-A1 | Combination treatment for diabetes mellitus | Nycomed GmbH (DE) | 2010-08-04 | — | — | EP | disclosed |
| US-20100179131-A1 | Combination treatment for diabetes mellitus | NYCOMED GMBH (DE) | 2010-07-15 | — | — | US | disclosed |
| US-20080214625-A1 | Roflumilast for the Treatment of Diabetes Mellitus | KONINKLIJKE HILIPS ELECTRONICS, N.V. (NL) | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129817-A1 | COMBINATION TREATMENT FOR DIABETES MELLITUS | GPR119, IAPP, MTNR1B | LMNA 3702/4885CYP3A4 413/4885CYP2C9 1520/4885 |
| US-20080214625-A1 | Roflumilast for the Treatment of Diabetes Mellitus | NOS3, PLAT, PTGIS | LMNA 3857/4885CYP3A4 421/4885CYP2C9 733/4885 |
| US-20110269750-A1 | ROFLUMILAST FOR THE TREATMENT OF DIABETES MELLITUS | PPARD, PPARA, PPARG | LMNA 3556/4885CYP3A4 553/4885CYP2C9 1219/4885 |
| US-20100179131-A1 | Combination treatment for diabetes mellitus | GPR119, GLP1R, MTNR1B | LMNA 3956/4885CYP3A4 328/4885CYP2C9 1165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.